Furthermore, as both EGFR and cMet are major oncogenic proteins in NSCLC with major contributions to tumor angiogenesis and contact-inhibition, we focused our efforts on determining whether EGFR and/or cMet mechanistically support phenotypic distinctions in monoclonal tumor cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.